<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Evidence suggests that <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) may share an underlying cause(s), a theory known as the 'common soil' hypothesis </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is central both to the progression from <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance to type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and to a constellation of <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> known as the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>These risk factors include visceral <z:hpo ids='HP_0001513'>obesity</z:hpo> and <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> characterized by low levels of <z:chebi fb="1" ids="47775">high-density lipoprotein cholesterol</z:chebi>, hypertriglyceridaemia and raised small dense <z:chebi fb="2" ids="39026">low-density lipoprotein</z:chebi> particle levels </plain></SENT>
<SENT sid="3" pm="."><plain>Changes in adipose tissue mass and metabolism may link <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and visceral <z:hpo ids='HP_0001513'>obesity</z:hpo>, a condition that is common in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, weight reduction, increased physical activity, <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="2376">acarbose</z:chebi> have been shown to reduce the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in genetically predisposed subjects and may decrease the high cardiovascular risk of patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Some fatty acid derivatives can affect energy metabolism by activating peroxisome proliferator-activated receptors (PPARs), nuclear receptors that play a key role in energy homeostasis </plain></SENT>
<SENT sid="6" pm="."><plain>These receptors represent an ideal therapeutic target for reducing cardiovascular risk, because they are involved in the regulation of both insulin action and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism </plain></SENT>
<SENT sid="7" pm="."><plain>In addition to lifestyle changes, PPARgamma <z:chebi fb="4" ids="48705">agonists</z:chebi> such as <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> are frequently beneficial and have been shown to ameliorate <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, while activation of PPARalpha (e.g. by fibrates) can lead to improvements in free fatty acid oxidation and <z:chebi fb="23" ids="18059">lipid</z:chebi> profile, and a reduction in cardiovascular events </plain></SENT>
<SENT sid="8" pm="."><plain>The development of agents with both PPARalpha and PPARgamma activity promises added benefits with amelioration of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, delayed progression to and of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and a reduction of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> </plain></SENT>
</text></document>